| [1] |
Sherlock S, Dooley J. Cholestasis[M]// Sherlock S, Dooley J. Disease of the liver and biliary system. 11th ed. Oxford: Blackwell Publishing, 2002: 219, 240.
|
| [2] |
Hilscher MB, Kamath PS, Eaton JE. Cholestatic liver diseases: a primer for generalists and subspecialists[J]. Mayo Clin Proc, 2020, 95(10): 2263-2279.
doi: 10.1016/j.mayocp.2020.01.015
pmid: 33012354
|
| [3] |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases[J]. J Hepatol, 2009, 51(2): 237-267.
doi: 10.1016/j.jhep.2009.04.009
URL
|
| [4] |
Xie W, Cao Y, Xu M, et al. Prognostic significance of elevated cholestatic enzymes for fibrosis and hepatocellular carcinoma in hospital discharged chronic viral hepatitis patients[J]. Sci Rep, 2017, 7(1): 10289.
doi: 10.1038/s41598-017-11111-5
URL
|
| [5] |
曹旬旬, 高月求, 张文宏, 等. 基于上海市住院慢性肝病患者胆汁淤积患病率的调查研究[J]. 中华肝脏病杂志, 2015, 23(8): 569-573.
|
| [6] |
Pieters A, Gijbels E, Cogliati B, et al. Biomarkers of cholestasis[J]. Biomark Med, 2021, 15(6): 437-454.
doi: 10.2217/bmm-2020-0691
pmid: 33709780
|
| [7] |
中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015)[J]. 中华肝脏病杂志, 2016, 19(6): 924-933.
|
| [8] |
中华医学会肝病学分会. 胆汁淤积性肝病管理指南(2021)[J]. 中华内科杂志, 2021, 60(12): 1075-1087.
|
| [9] |
Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited[J]. Hepatology, 2002, 36(3): 525-531.
pmid: 12198643
|
| [10] |
Appanna G, Kallis Y. An update on the management of cholestatic liver diseases[J]. Clin Med (Lond), 2020, 20(5): 513-516.
|
| [11] |
Wagner M, Fickert P. Drug therapies for chronic cholestatic liver diseases[J]. Annu Rev Pharmacol Toxicol, 2020, 60:503-527.
doi: 10.1146/annurev-pharmtox-010818-021059
URL
|
